Project Grant R41CA298176
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The University of Pennsylvania received a $597,766 Project Grant from the National Cancer Institute (CFDA Program 93.394 - Cancer Detection and Diagnosis Research) to develop methods for dual-tracer multiparametric imaging with a long-axial field-of-view PET scanner. The project aims to enable the simultaneous imaging of two different PET radiotracers in a single session, which would improve the characterization of cancer and transform precision medicine guided by molecular imaging. The 5-year...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
- This Project Grant award from the National Cancer Institute's (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a research project titled "Innovative Scan Protocols with Combined Long Axial FOV PET and Spectral CT for Improved Quantification in Oncology". The $666,670 award, effective January 15, 2025, aims to develop advanced imaging protocols and processing techniques that utilize both positron emission tomography (PET) and spectral computed tomography (CT) to enhance...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- This $149,394 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant supports research led by the University of California, Davis to advance the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. Specifically, the research focuses on designing, synthesizing, and optimizing novel molecular imaging...
- This $671,072 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel microdevice to measure malignant lipid signaling in single cells from clinical samples. The University of Washington will lead a multidisciplinary collaboration to create a "picoliter thin-layer chromatography" (PTLC) chip and supporting hardware, integrating bioengineering, chemistry, and oncology expertise. This...
- The federal Project Grant was awarded by the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $764,448 grant was awarded to Cereus Diagnostics Corp. on August 1, 2025 to develop Lung-FAST, a rapid and cost-effective PCR-based test that can detect clinically actionable genetic mutations in lung cancer samples with high accuracy, even from small biopsy samples. The key...
- This $431,970 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research at Albert Einstein College of Medicine to develop a tool that visualizes the distribution of Listeria bacteria in vivo using Positron Emission Tomography (PET) scanning. The goal is to monitor the accumulation of Listeria, which has been used as a novel immunotherapeutic approach to selectively deliver tumor antigens to tumors, in order to...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $401,115 Project Grant to Thomas Jefferson University's Sidney Kimmel Medical College to evaluate the use of contrast-enhanced ultrasound (CEUS) in assessing the response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE) treatment. The project aims to assess both qualitative and quantitative CEUS as a tool for evaluating HCC treatment response to TARE, including investigating...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $881,647 Project Grant to Panome Bio Inc. under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The grant supports research to advance untargeted metabolomics approaches for biomarker discovery in colon cancer. Specifically, Panome Bio is developing novel software and analytical methods to enhance the value and impact of untargeted metabolomics by addressing...